AMD THERAPY: A Screen for Molecules that Promote RPE Survival and Differentiation
AMD 疗法:促进 RPE 存活和分化的分子筛选
基本信息
- 批准号:8575156
- 负责人:
- 金额:$ 20.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adherent CultureAge related macular degenerationApoptoticAtrophicAutologousAutomobile DrivingBiological AssayBiologyBlindnessCell SurvivalCell TransplantationCellsCessation of lifeCytoprotectionDataDevelopmentDiseaseElderlyEpithelialFunctional disorderHealthHumanInjuryLeadLengthMeasuresMediatingMolecular ProbesMonophenol MonooxygenaseOxidative StressPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhenotypePhotoreceptorsPlayPluripotent Stem CellsProcessResearch PersonnelResidual stateRetinal PigmentsRoleSourceStem cellsStressStructure of retinal pigment epitheliumTechnologyTestingTherapeuticTransplantationVisionWestern WorldWorkbasebevacizumabfetalfetus cellhigh throughput screeninghuman embryonic stem cellhuman stem cellsimprovedinsightneovascularnovelnovel therapeuticsoxidationoxidative damagepromoterpublic health relevanceresponsescreeningsmall moleculesmall molecule librariesstemstem cell differentiationtooltreatment strategy
项目摘要
DESCRIPTION (provided by applicant): The atrophic ("dry") form of age-related macular degeneration (AMD), which is the most common form of the disease, is largely untreatable. Accumulating evidence suggests that dysfunction and loss of retinal pigment epithelial (RPE) cells plays an important role in the pathophysiology of AMD. Efforts have therefore been made to A) develop agents that promote RPE health and survival and B) develop cell transplantation-based approaches to replace the dysfunctional and lost RPE cells. In this application we propose to take complementary High Throughput Screening (HCS) and High Content Screening (HCS) approaches to identify small molecules that promote the survival of human stem cell-derived RPE cells exposed to oxidative stress (Specific Aim 1) and molecules that promote the differentiation of stem cells towards an RPE phenotype (Specific Aim 2). Given that oxidative stress has been implicated in AMD, the molecules identified in Aim 1 will hopefully serve as lead molecules for the development of cytoprotective approaches for dry AMD therapy. And the molecules identified in Aim 2 will hopefully aid in the development of improved cell-based treatment approaches for dry AMD. In addition, the molecules from both aims will also serve as molecular probes that will be useful in study of the mechanisms that determine RPE differentiation and that modulate the RPE cell's response to oxidative stress.
描述(由申请人提供):萎缩性(“干性”)形式的年龄相关性黄斑变性(AMD)是该疾病最常见的形式,在很大程度上是无法治疗的。越来越多的证据表明,视网膜色素上皮 (RPE) 细胞的功能障碍和丧失在 AMD 的病理生理学中起着重要作用。因此,人们努力 A) 开发促进 RPE 健康和存活的药物,B) 开发基于细胞移植的方法来替代功能失调和丢失的 RPE 细胞。在此应用中,我们建议采用互补的高通量筛选 (HCS) 和高内涵筛选 (HCS) 方法来识别促进暴露于氧化应激的人类干细胞衍生的 RPE 细胞存活的小分子(具体目标 1)以及促进干细胞向 RPE 表型分化(具体目标 2)。鉴于氧化应激与 AMD 相关,Aim 1 中鉴定的分子有望成为开发干性 AMD 疗法的细胞保护方法的先导分子。 Aim 2 中确定的分子有望有助于开发改进的干性 AMD 细胞治疗方法。此外,这两个目标的分子也将用作分子探针,可用于研究决定 RPE 分化和调节 RPE 细胞对氧化应激反应的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donald J. Zack其他文献
Resolving complex research data management issues in biomedical laboratories: Qualitative study of an industry-academia collaboration
解决生物医学实验室复杂的研究数据管理问题:产学界合作的定性研究
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Sahiti Myneni;Vimla L. Patel;G. S. Bova;Jian Wang;Christopher F. Ackerman;C. Berlinicke;Steve H. Chen;M. Lindvall;Donald J. Zack;Y. Shafranovich - 通讯作者:
Y. Shafranovich
Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization.
碱性成纤维细胞生长因子对于视网膜新生血管的发展既不是必要的也不是充分的。
- DOI:
10.1016/s0002-9440(10)65619-2 - 发表时间:
1998-09-01 - 期刊:
- 影响因子:0
- 作者:
Hiroaki Ozaki;N. Okamoto;S. Ortega;Michelle Chang;Keiko Ozaki;Srinivas R. Sadda;M. A. Vinores;N. Derevjanik;Donald J. Zack;Claudio Basilico;P. Campochiaro;Maumenee - 通讯作者:
Maumenee
Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats.
工程肽-药物缀合物通过局部给药为大鼠提供对视网膜神经节细胞的持续保护。
- DOI:
10.1016/j.jconrel.2023.08.058 - 发表时间:
2023-08-30 - 期刊:
- 影响因子:0
- 作者:
Henry T. Hsueh;Renee Ti Chou;U. Rai;Patricia Kolodziejski;Wathsala Liyanage;Jahnavi Pejavar;Ann Mozzer;Charlotte Davison;Matthew B Appell;Yoo Chun Kim;Kirby T Leo;HyeYoung Kwon;Maanasa Sista;Nicole M. Anders;Avelina Hemingway;S. Rompicharla;I. Pitha;Donald J. Zack;J. Hanes;Michael P Cummings;L. Ensign - 通讯作者:
L. Ensign
A novel approach to increase glial cell populations in brain microphysiological systems
一种增加大脑微生理系统中神经胶质细胞数量的新方法
- DOI:
10.1101/2023.09.14.557775 - 发表时间:
2023-09-15 - 期刊:
- 影响因子:0
- 作者:
I. M. Pantoja;Lixuan Ding;P. E. C. Leite;S. A. Marques;J. C. Romero;Dowlette;Donald J. Zack;Xitiz Chamling;Lena Smirnova - 通讯作者:
Lena Smirnova
Nonviral ocular gene transfer
非病毒眼部基因转移
- DOI:
10.1038/sj.gt.3302475 - 发表时间:
2005-05-01 - 期刊:
- 影响因子:5.1
- 作者:
S. Kachi;Yuji Oshima;Noriko Esumi;M. Kachi;Brian S. Rogers;Donald J. Zack;P. Campochiaro - 通讯作者:
P. Campochiaro
Donald J. Zack的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donald J. Zack', 18)}}的其他基金
Role of OPA1 in Retinal Ganglion Cell Differentiation and the Pathogenesis of Dominant Optic Atrophy
OPA1在视网膜神经节细胞分化和显性视神经萎缩发病机制中的作用
- 批准号:
10705002 - 财政年份:2022
- 资助金额:
$ 20.25万 - 项目类别:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
双亮氨酸拉链激酶 (DLK) 作为视网膜神经节细胞损伤的调节剂
- 批准号:
9127253 - 财政年份:2013
- 资助金额:
$ 20.25万 - 项目类别:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
双亮氨酸拉链激酶 (DLK) 作为视网膜神经节细胞损伤的调节剂
- 批准号:
8925084 - 财政年份:2013
- 资助金额:
$ 20.25万 - 项目类别:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
双亮氨酸拉链激酶 (DLK) 作为视网膜神经节细胞损伤的调节剂
- 批准号:
8573119 - 财政年份:2013
- 资助金额:
$ 20.25万 - 项目类别:
AMD THERAPY: A Screen for Molecules that Promote RPE Survival and Differentiation
AMD 疗法:促进 RPE 存活和分化的分子筛选
- 批准号:
8703116 - 财政年份:2013
- 资助金额:
$ 20.25万 - 项目类别:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
双亮氨酸拉链激酶 (DLK) 作为视网膜神经节细胞损伤的调节剂
- 批准号:
8725166 - 财政年份:2013
- 资助金额:
$ 20.25万 - 项目类别:
NEURITIN:novel RGC neurotrophic factor and potential target for glaucoma therapy
NEURITIN:新型RGC神经营养因子和青光眼治疗的潜在靶点
- 批准号:
7565586 - 财政年份:2009
- 资助金额:
$ 20.25万 - 项目类别:
NEURITIN:novel RGC neurotrophic factor and potential target for glaucoma therapy
NEURITIN:新型RGC神经营养因子和青光眼治疗的潜在靶点
- 批准号:
7895521 - 财政年份:2009
- 资助金额:
$ 20.25万 - 项目类别:
Protein kinase inhibitors that promote RGC survival and function
促进 RGC 存活和功能的蛋白激酶抑制剂
- 批准号:
7706852 - 财政年份:2009
- 资助金额:
$ 20.25万 - 项目类别:
Protein kinase inhibitors that promote RGC survival and function
促进 RGC 存活和功能的蛋白激酶抑制剂
- 批准号:
7934529 - 财政年份:2009
- 资助金额:
$ 20.25万 - 项目类别:
相似国自然基金
年龄相关性黄斑变性治疗中双靶向药物递释策略及其机制研究
- 批准号:82301217
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
GNAS介导OPN4-PLCβ4-TRPC6/7通路调节自主感光视网膜神经节细胞在年龄相关性黄斑变性中的作用机制研究
- 批准号:82301229
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
HTRA1介导CTRP5调控脂代谢通路在年龄相关性黄斑变性中的致病机制研究
- 批准号:82301231
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
视网膜色素上皮细胞中NAD+水解酶SARM1调控自噬溶酶体途径参与年龄相关性黄斑变性的机制研究
- 批准号:82301214
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向年龄相关性黄斑变性诊断的迁移学习算法研究
- 批准号:62371328
- 批准年份:2023
- 资助金额:53 万元
- 项目类别:面上项目
相似海外基金
Nanoparticle-Based Tracking of Retinal Ganglion Cell Transplant
基于纳米颗粒的视网膜神经节细胞移植追踪
- 批准号:
10663516 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Bcl-2, Subretinal Scar Formation and Neovascular AMD
Bcl-2、视网膜下疤痕形成和新生血管性 AMD
- 批准号:
10733960 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection
评估丁酸前药纳米颗粒在视网膜神经保护中的功效
- 批准号:
10602346 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Nanoparticle-Based Tracking of Retinal Ganglion Cell Transplant
基于纳米颗粒的视网膜神经节细胞移植追踪
- 批准号:
10663516 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Identification of novel phosphodiesterase (PDE)-modulating compounds and characterization of associated cytoprotective pathways in lightdamagedretina
光损伤视网膜中新型磷酸二酯酶 (PDE) 调节化合物的鉴定和相关细胞保护途径的表征
- 批准号:
10418610 - 财政年份:2021
- 资助金额:
$ 20.25万 - 项目类别: